A fucose analog that inhibits Dll-induced Notch signaling by reducing Notch ligand Dll1-Notch1 binding, but not Jag1.

A fourth-generation fluoroquinolone antibiotic that inhibits the bacterial DNA gyrase and topoisomerase IV.

A fourth-generation fluoroquinolone antibiotic that inhibits the bacterial DNA gyrase and topoisomerase IV.

A fourth-generation fluoroquinolone antibiotic that inhibits the bacterial DNA gyrase and topoisomerase IV.

A form of dynorphin and an endogenous opioid peptide with the amino acid sequence: Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys..

A first-in-class, small molecule protein-protein inhibitor of the interaction between the E1 and E2 proteins of HPV types 6 and 11.

A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively.

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A first-in-class, dual inhibitor of PDE5 and HDAC that inhibits HDAC1/2/3/6 (IC50=310/490/322/91 nM, respectively) and PDE5 (IC50=60 nM).

A first-in-class antitumor and antimetastatic agent that induces necrosis in breast cancer tumors, inhibits inhibit mitochondria complex I activity and reduces HIF-1α stabilization.

A first-generation antihistamine that acts primarily as H1 receptor antagonist.

A dual inhibitor of TNF-α and TGF-β1 by inhibiting IκB kinase phosphorylation and Smad3 phosphorylation.

A dual inhibitor of E selectin and CXCR4 with IC50 of 4.1 uM and 30 nM respectively, blocks adhesion of AML blasts to E-Selectin, mobilizes human AML engrafted in mice.

A dual inhibitor of E selectin and CXCR4 with IC50 of 3.6 uM and 1.1 uM respectively, blocks adhesion of AML blasts to E-Selectin, mobilizes human AML engrafted in mice.

A dual antagonist of TP1 and EP4 receptors that inhibit TXA2-induced platelet aggregation with IC50 of 0.26 uM.

A dual action as an alkylating agent and topoisomerase inhibitor with potent activity against anthracycline- and cisplatin-resistant tumor cancer.

A drug-like small molecule that prevents aminoglycoside-induced hair cell death in zebrafish and in mammals..

A doxorubicin analog that demonstrates anti-cancer activity without cardiotoxicity, does not inhibit topoisomerase IIβ activity at 100 uM.

A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates.

A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates.

A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates.

A direct soluble guanylate cyclase (sGC) stimulator that acts independently of nitric oxide (NO).

A dipeptide antibiotic that inhibits the initiation of protein synthesis.

A derivative of 8-hydroxyquinoline that has selectivity for rescuing the distinct toxicities caused by the expression of TDP-43, α-synuclein or polyglutamine proteins.

A cytokinin analog that displays potent antiproliferative activity against various human cancer cell lines.

A counterstain for background autofluorescence in fluorescence and immunofluorescence histochemistry, also is the first small molecule prion protein (PrP) ligand capable of inhibiting Aβ binding.

A coumarin-based HIV-1 viral protein R (Vpr) inhibitor, inhibits Vpr-dependent viral infection of human macrophages.

A conjugate of glucose and active alkylating moiety of ifosfamide with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters.

A combined adenosine receptor antagonist, p38 MAPK and PDE4 inhibitor, inhibits A1, A2b and A3 receptor (IC50=19, 21 and 80 nM), p38α, p38β and PDE4D (IC50=87, 400 and 22 nM).